文章摘要

三阴性乳腺癌的生物标记物研究进展

作者: 1吴至佛, 1汪灵, 1黄俊辉
1 中南大学湘雅医院 肿瘤科，湖南 长沙 410008
通讯: 吴至佛 Email: wuzhifo@pwtt.com
DOI: 10.3978/.10.3978/j.issn.1005-6947.2017.11.016

摘要

三阴性乳腺癌(TNBC)是指雌激素受体(ER)、孕激素受体(PR)和表皮生长因子受体 2(HER-2) 均为阴性的乳腺癌，以发病年龄轻、易早期发生转移为特点。TNBC 对 ER、PR 为靶点的内分泌治疗 和以 HER-2 为靶点的靶向药物治疗无效，已成为乳腺癌治疗的难点与研究的热点。为改进 TNBC 的 临床诊断与治疗手段，学者们做了大量的研究来寻找更多新的生物标记物。笔者对近年来国内外关于 TNBC 的生物标记物研究进展进行综述。
关键词： 三阴性乳腺癌 生物标记，肿瘤 综述文献

Research progress on biomarkers of triple-negative breast cancer

Authors: 1Wu Zhifo, 1Wang Ling, 1Huang Junhui
1 Department of Oncology, Xiangya Hospital, Central South University, Changsha 410008, China

CorrespondingAuthor:Wu Zhifo Email: wuzhifo@pwtt.com

Abstract

Triple-negative breast cancer (TNBC) is a subtype of breast cancer defined as the absence of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2), and characterized by onset at a younger age and high incidence of early metastasis. TNBC does not respond to endocrine therapy targeting ER or PR and HER-2-targeted agents, and has accordingly become a challenge in clinical treatment and a hotspot in research of breast cancer. A great number of investigations have been done by scholars for finding new biomarkers of TNBC and thereby improving its clinical diagnosis and treatment. Here, the authors present the recent progress on researches concerning the biomarkers of TNBC both at home and abroad.
Keywords： Triple Negative Breast Neoplasms biomarkers tumor Review